The first two authors contributed equally to this work.
Testing mouse mammary tumor virus superantigen as adjuvant in cytotoxic T-lymphocyte responses against a melanoma tumor antigen
Article first published online: 12 MAR 2002
Copyright © 2002 Wiley-Liss, Inc.
International Journal of Cancer
Volume 99, Issue 2, pages 201–206, 10 May 2002
How to Cite
Wirth, S., Bille, F., Koenig, S., Wehrli, N., Miconnet, I., Lévy, F., Diggelmann, H., Romero, P. and Acha-Orbea, H. (2002), Testing mouse mammary tumor virus superantigen as adjuvant in cytotoxic T-lymphocyte responses against a melanoma tumor antigen. Int. J. Cancer, 99: 201–206. doi: 10.1002/ijc.10237
- Issue published online: 11 APR 2002
- Article first published online: 12 MAR 2002
- Manuscript Accepted: 16 NOV 2001
- Manuscript Revised: 12 NOV 2001
- Manuscript Received: 29 AUG 2001
- Giorgio Cavaglieri Foundation
- Swiss National Science Foundation. Grant Number: 31-59165.99
- vaccinia virus;
- tumor immunology;
- mouse mammary tumor virus;
- cytotoxic T lymphocyte
Cytotoxic T cells represent a powerful strategy for antitumor treatment. Depending on the route of injection, an important role for CD4 T cell–mediated help was observed in the induction of this response. For this reason, we investigated whether induction of a CTL response to the HLA-A2–restricted immunodominant peptide melanoma antigen Melan-A was improved by using rVVs expressing the CTL-defined epitope alone or in combination with an SAg. In the latter case, the few infected dendritic cells simultaneously presented an SAg and an antigen, i.e., peptide. Here, we show that the anti-Melan-A response was efficiently induced but not significantly improved by coexpression of the SAg. © 2002 Wiley-Liss, Inc.